Logo image of AB.PA

AB SCIENCE SA (AB.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:AB - FR0010557264 - Common Stock

1.372 EUR
0 (-0.29%)
Last: 1/21/2026, 7:00:00 PM
Fundamental Rating

1

AB gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 54 industry peers in the Pharmaceuticals industry. AB may be in some trouble as it scores bad on both profitability and health. AB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • AB had negative earnings in the past year.
  • AB had a negative operating cash flow in the past year.
  • In the past 5 years AB always reported negative net income.
  • In the past 5 years AB reported 4 times negative operating cash flow.
AB.PA Yearly Net Income VS EBIT VS OCF VS FCFAB.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -40.25%, AB is doing worse than 81.48% of the companies in the same industry.
Industry RankSector Rank
ROA -40.25%
ROE N/A
ROIC N/A
ROA(3y)-45.97%
ROA(5y)-51.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AB.PA Yearly ROA, ROE, ROICAB.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

  • The Gross Margin of AB (90.75%) is better than 94.44% of its industry peers.
  • AB's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for AB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.74%
GM growth 5Y5.64%
AB.PA Yearly Profit, Operating, Gross MarginsAB.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

0

2. Health

2.1 Basic Checks

  • AB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AB has been increased compared to 1 year ago.
  • Compared to 5 years ago, AB has more shares outstanding
  • Compared to 1 year ago, AB has a worse debt to assets ratio.
AB.PA Yearly Shares OutstandingAB.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
AB.PA Yearly Total Debt VS Total AssetsAB.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -19.84, we must say that AB is in the distress zone and has some risk of bankruptcy.
  • AB has a worse Altman-Z score (-19.84) than 83.33% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.84
ROIC/WACCN/A
WACC7.52%
AB.PA Yearly LT Debt VS Equity VS FCFAB.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M -30M

2.3 Liquidity

  • A Current Ratio of 0.67 indicates that AB may have some problems paying its short term obligations.
  • The Current ratio of AB (0.67) is worse than 87.04% of its industry peers.
  • A Quick Ratio of 0.67 indicates that AB may have some problems paying its short term obligations.
  • The Quick ratio of AB (0.67) is worse than 77.78% of its industry peers.
Industry RankSector Rank
Current Ratio 0.67
Quick Ratio 0.67
AB.PA Yearly Current Assets VS Current LiabilitesAB.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

2

3. Growth

3.1 Past

  • The earnings per share for AB have decreased strongly by -23.25% in the last year.
  • The Revenue has decreased by -5.08% in the past year.
  • Measured over the past years, AB shows a decrease in Revenue. The Revenue has been decreasing by -7.36% on average per year.
EPS 1Y (TTM)-23.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.33%
Revenue 1Y (TTM)-5.08%
Revenue growth 3Y-12.62%
Revenue growth 5Y-7.36%
Sales Q2Q%-8.04%

3.2 Future

  • The Earnings Per Share is expected to grow by 30.66% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, AB will show a decrease in Revenue. The Revenue will decrease by -4.65% on average per year.
EPS Next Y68.29%
EPS Next 2Y30.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-9.09%
Revenue Next 2Y-4.65%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AB.PA Yearly Revenue VS EstimatesAB.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
AB.PA Yearly EPS VS EstimatesAB.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • AB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AB.PA Price Earnings VS Forward Price EarningsAB.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AB.PA Per share dataAB.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AB's earnings are expected to grow with 30.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.66%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • AB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

AB SCIENCE SA

EPA:AB (1/21/2026, 7:00:00 PM)

1.372

0 (-0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-30
Earnings (Next)05-11
Inst Owners0.12%
Inst Owner ChangeN/A
Ins Owners30.8%
Ins Owner ChangeN/A
Market Cap90.80M
Revenue(TTM)1.03M
Net Income(TTM)-8.54M
Analysts84.44
Price Target4.31 (214.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.25%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)65.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 88.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.02
BVpS-0.41
TBVpS-0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.25%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.75%
FCFM N/A
ROA(3y)-45.97%
ROA(5y)-51.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.74%
GM growth 5Y5.64%
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.43%
Cap/Sales 19.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.67
Quick Ratio 0.67
Altman-Z -19.84
F-Score3
WACC7.52%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)39.08%
Cap/Sales(5y)35.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.33%
EPS Next Y68.29%
EPS Next 2Y30.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.08%
Revenue growth 3Y-12.62%
Revenue growth 5Y-7.36%
Sales Q2Q%-8.04%
Revenue Next Year-9.09%
Revenue Next 2Y-4.65%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.23%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y61.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.21%
OCF growth 3YN/A
OCF growth 5YN/A

AB SCIENCE SA / AB.PA FAQ

What is the fundamental rating for AB stock?

ChartMill assigns a fundamental rating of 1 / 10 to AB.PA.


What is the valuation status for AB stock?

ChartMill assigns a valuation rating of 1 / 10 to AB SCIENCE SA (AB.PA). This can be considered as Overvalued.


What is the profitability of AB stock?

AB SCIENCE SA (AB.PA) has a profitability rating of 1 / 10.


How financially healthy is AB SCIENCE SA?

The financial health rating of AB SCIENCE SA (AB.PA) is 0 / 10.


What is the expected EPS growth for AB SCIENCE SA (AB.PA) stock?

The Earnings per Share (EPS) of AB SCIENCE SA (AB.PA) is expected to grow by 68.29% in the next year.